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Background
To demonstrate that autoantibodies targeting a p140 pro-
tein are a major autoantigen in juvenile dermatomyositis
(JDM) and describe the clinical associations in children
recruited to the JDM Registry (JDRR).
Methods
156 children were studied. Serum was screened by
immunofluorescence (IF) and radio-immunoprecipita-
tion (IPP) [1]. Immunodepletion was used to establish
whether p140 is different to p155/140 also recognised in
JDM [1].
Results
21% of children were positive for anti-p140 on IPP, with
a weak non-specific nuclear pattern or negative ANA on
IF. No anti-p140 cases were positive for other autoanti-
body specificities. Immunodepletion confirmed that
p140 and p155/140 are different autoantigens. Anti-p140
positives compared to negatives had a similar male:female
ratio and age at diagnosis. No significant difference was
observed in the type or distribution of rash when compar-
ing anti-p140 positives vs. negatives except for more rash
on the trunk in negative cases (p = 0.017). Calcinosis was
significantly more frequent in anti-p140 positives (52%)
compared to negatives (13%) (p < 0.001, OR 7.1 95% CI
3–16.8). When comparing anti-p140 and anti-p155/140
cases; cutaneous oedema (p = 0.04) and rash over the
trunk (p = 0.002) and small joints (p = 0.013) was more
frequent in anti-p155/140. Calcinosis in anti-p140
remained a significant feature compared to anti-p155/140
(p = 0.005, OR 6.4 95% CI 2–22).
Conclusion
Anti-p140 found in this cohort is likely to be the same as
anti-MJ, described against nuclear matrix protein NXP-2
[2]; further confirmation is required. Anti-p140 is a major
autoantibody subset in JDM. Further characterisation of
this system will provide insights into the pathophysiology
of calcinosis in JDM.
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